| scholarly article | Q13442814 |
| P50 | author | Raph L Hamers | Q62750853 |
| Wendy S Stevens | Q93356282 | ||
| Akin Osibogun | Q93360232 | ||
| Ferdinand Wnm Wit | Q94948239 | ||
| Carole L Wallis | Q98650968 | ||
| Immaculate Nankya | Q101823355 | ||
| Tobias F Rinke de Wit | Q101823445 | ||
| Francesca Conradie | Q102975495 | ||
| Kim C E Sigaloff | Q114072173 | ||
| Michèle van Vugt | Q114323013 | ||
| Maureen Muller | Q115804157 | ||
| Margaret Siwale | Q117271277 | ||
| Mariette E Botes | Q117271278 | ||
| Kishor Mandaliya | Q117271279 | ||
| PharmAccess African Studies to Evaluate Resistance (PASER) | Q117271281 | ||
| Cissy Kityo | Q42754393 | ||
| P2093 | author name string | Rob Schuurman | |
| P2860 | cites work | The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. | Q50745207 |
| The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes | Q56778335 | ||
| Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance | Q59700719 | ||
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration | Q24792432 | ||
| Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy | Q28473296 | ||
| Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update | Q28474918 | ||
| An automated genotyping system for analysis of HIV-1 and other microbial sequences | Q33220974 | ||
| TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories | Q33824827 | ||
| Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. | Q34102202 | ||
| Time trends in primary HIV-1 drug resistance among recently infected persons | Q34136709 | ||
| Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. | Q34387810 | ||
| Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa | Q34606742 | ||
| Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. | Q36673315 | ||
| Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis | Q36833511 | ||
| The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance | Q37168034 | ||
| Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis | Q37531320 | ||
| Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 | ||
| Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala | Q38870642 | ||
| Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda | Q38876159 | ||
| High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. | Q38882038 | ||
| Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance | Q38884246 | ||
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management | Q40396257 | ||
| Transmission of drug-resistant HIV-1 is stabilizing in Europe | Q44591236 | ||
| Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study | Q45057839 | ||
| A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). | Q45895415 | ||
| The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models | Q46193879 | ||
| Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 | ||
| Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. | Q46520376 | ||
| Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects | Q46758196 | ||
| HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia | Q48064215 | ||
| P433 | issue | 10 | |
| P921 | main subject | Sub-Saharan Africa | Q132959 |
| multicenter clinical trial | Q6934595 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 750-759 | |
| P577 | publication date | 2011-07-27 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study | |
| P478 | volume | 11 |
| Q37026509 | A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only |
| Q47558450 | Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda. |
| Q38854117 | Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa |
| Q36498538 | Adherence to antiretroviral therapy and treatment outcomes among conflict-affected and forcibly displaced populations: a systematic review |
| Q61447237 | Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015 |
| Q38913062 | Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis |
| Q30486897 | An affordable HIV-1 drug resistance monitoring method for resource limited settings |
| Q33597247 | Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia |
| Q45996863 | Antiretroviral drug resistance in resource-limited settings. |
| Q36419479 | Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda |
| Q28270788 | Antiretroviral prophylaxis for HIV prevention in heterosexual men and women |
| Q37494332 | Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa |
| Q38067503 | Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years? |
| Q36113560 | Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. |
| Q58780819 | Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
| Q56912942 | Assessment of a quality improvement intervention to strengthen pharmaceutical human resources and improve availability and use of HIV medicines in Uganda |
| Q51787421 | Barriers to simplified HIV treatment in low-resource settings. |
| Q92983680 | Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa |
| Q36571900 | Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo |
| Q38855121 | CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population |
| Q27026923 | Challenges and opportunities for the implementation of virological testing in resource-limited settings |
| Q89900309 | Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread |
| Q36144731 | Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa |
| Q28539927 | Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China |
| Q38898453 | Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance |
| Q28534376 | Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients |
| Q36224801 | Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa |
| Q28482138 | Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring |
| Q92561109 | Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens |
| Q28540368 | Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity |
| Q33810988 | Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012 |
| Q38539190 | Defeating AIDS--advancing global health |
| Q28533216 | Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in Spain |
| Q34398331 | Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective |
| Q37026352 | Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots |
| Q35758605 | Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections |
| Q42238359 | Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade |
| Q91757237 | Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa |
| Q38208721 | Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review |
| Q37107955 | Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho |
| Q39043035 | Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study |
| Q34920087 | Effective coverage for antiretroviral therapy in a Ugandan district with a decentralized model of care |
| Q41020993 | Effectiveness of first-line antiretroviral therapy in HIV/AIDS patients: A 5-year longitudinal evaluation in Fujian Province, Southeast China |
| Q36134243 | Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China |
| Q28534568 | Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study |
| Q39932884 | Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis |
| Q36669337 | Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits |
| Q37447287 | Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains. |
| Q28484825 | Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors |
| Q45326389 | Expansion of Viral Load Testing and the Potential Impact on Human Immunodeficiency Virus Drug Resistance |
| Q27677405 | Extreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuran |
| Q36667251 | Genital Shedding of Resistant Human Immunodeficiency Virus-1 Among Women Diagnosed With Treatment Failure by Clinical and Immunologic Monitoring |
| Q47560008 | Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings |
| Q37216235 | Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis |
| Q37062207 | HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda |
| Q41906976 | HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya |
| Q34549498 | HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya |
| Q55256755 | HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique. |
| Q36158371 | HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument |
| Q34498574 | HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial |
| Q88676449 | HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability |
| Q28271593 | HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing |
| Q50052129 | HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe. |
| Q57207278 | HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials |
| Q34280466 | HIV-1 antiretroviral resistance: scientific principles and clinical applications |
| Q28542528 | HIV-1 diversity, transmission dynamics and primary drug resistance in Angola |
| Q46771737 | HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa |
| Q86178001 | HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa |
| Q34993070 | HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania |
| Q42360505 | HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis |
| Q64101093 | HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon |
| Q42286083 | HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection |
| Q41931227 | HIV-1 genetic diversity, geographical linkages and antiretroviral drug resistance among individuals from Pakistan. |
| Q28482189 | HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone |
| Q42919016 | HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness, and public health impact |
| Q37580882 | HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study |
| Q57031109 | HIV-1C proviral DNA for detection of drug resistance mutations |
| Q57285998 | HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013 |
| Q37410105 | High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children. |
| Q41929325 | High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors |
| Q89677790 | High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy. |
| Q47559042 | Hiv Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy: Hptn 052. |
| Q59355880 | Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel |
| Q37003072 | Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa |
| Q36294353 | Implementation and Operational Research: Risk Factors of Loss to Follow-up Among HIV-Positive Pediatric Patients in Dar es Salaam, Tanzania |
| Q36005551 | In vitro antiretroviral activity and in vivo toxicity of the potential topical microbicide copper phthalocyanine sulfate |
| Q28477624 | Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population |
| Q36957786 | Increasing HIV-1 pretreatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya |
| Q56911534 | Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013 |
| Q37216052 | Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina |
| Q45323778 | Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries |
| Q36509589 | Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya |
| Q28481603 | Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010 |
| Q28535266 | Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda |
| Q28728304 | Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients |
| Q28543986 | Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR |
| Q33759577 | Misdiagnosis of HIV treatment failure based on clinical and immunological criteria in Eastern and Central Kenya |
| Q35619584 | Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance |
| Q28554729 | Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey |
| Q28482242 | Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda |
| Q42262381 | Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia |
| Q40599667 | Molecular epidemiology of co-infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, Zimbabwe |
| Q41925810 | Multi-scale immunoepidemiological modeling of within-host and between-host HIV dynamics: systematic review of mathematical models |
| Q37146865 | No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana |
| Q34339340 | Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. |
| Q35629306 | Origin and Population Dynamics of a Novel HIV-1 Subtype G Clade Circulating in Cape Verde and Portugal |
| Q38962278 | Patterns of HIV-1 Drug-Resistance Mutations among Patients Failing First-Line Antiretroviral Treatment in South India |
| Q39043026 | Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies |
| Q28537726 | Patterns of transmitted HIV drug resistance in Europe vary by risk group |
| Q33849840 | Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe |
| Q64242149 | Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens |
| Q31150044 | Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes |
| Q41143073 | Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy |
| Q34359213 | Phylodynamics of HIV-1 subtype C epidemic in east Africa |
| Q28080301 | Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How |
| Q36049082 | Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010. |
| Q53694036 | Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. |
| Q42225318 | Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea |
| Q38858252 | Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. |
| Q38849814 | Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children |
| Q37173887 | Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens |
| Q85509608 | Pretreatment HIV-1 drug resistance testing in sub-Saharan Africa |
| Q36186007 | Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project |
| Q28486101 | Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009) |
| Q47609679 | Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014. |
| Q28553024 | Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay |
| Q89561606 | Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda |
| Q58563027 | Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance |
| Q64093598 | Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India |
| Q34129300 | Primary drug resistance in South Africa: data from 10 years of surveys |
| Q28538242 | Profile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago |
| Q39043678 | Promises and pitfalls of Illumina sequencing for HIV resistance genotyping |
| Q46358497 | Public health. Getting HIV treatment to the most people |
| Q39033763 | Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial |
| Q34969496 | Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review |
| Q90615370 | Reasons for first line ART modification over the years during the ART scale up in Uganda |
| Q37267332 | Regional differences in predictive accuracy of WHO immunologic failure criteria |
| Q43104165 | Reply to Gonzalez-Serna et al. |
| Q35591789 | Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors |
| Q91895609 | Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study |
| Q36794795 | Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance |
| Q36795920 | Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria |
| Q37543203 | Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria |
| Q38849889 | Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? |
| Q91877322 | Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure |
| Q28660673 | Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay |
| Q33740286 | Spatiotemporal dynamics of the HIV-1 subtype G epidemic in West and Central Africa |
| Q35909838 | Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20 |
| Q36274049 | Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya |
| Q34346783 | Surveillance of transmitted HIV drug resistance in antiretroviral-naive patients aged less than 25 years, in Bangkok, Thailand |
| Q34625910 | Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa |
| Q37354106 | The Art of HIV Elimination: Past and Present Science |
| Q36675129 | The demise of multidrug-resistant HIV-1: the national time trend in Portugal |
| Q37455928 | The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa |
| Q89629287 | The long-term effects of a family based economic empowerment intervention (Suubi+Adherence) on suppression of HIV viral loads among adolescents living with HIV in southern Uganda: Findings from 5-year cluster randomized trial |
| Q41159447 | The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China |
| Q85014831 | Time to get serious about HIV antiretroviral resistance |
| Q40425066 | Time to get serious with HIV-1 resistance in sub-Saharan Africa |
| Q37495405 | Transmitted HIV drug resistance in treatment-naive Romanian patients |
| Q33820125 | Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia |
| Q40983086 | Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan |
| Q35827900 | Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period |
| Q64245959 | Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis |
| Q35917578 | Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011 |
| Q38209874 | Update on antiretroviral treatment during primary HIV infection |
| Q46662332 | Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study |
| Q33668468 | Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans |
| Q58760170 | Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings |
| Q28551745 | Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda |
| Q99712910 | Whatman FTA cards versus plasma specimens for the quantitation of HIV-1 RNA using two real-time PCR assays |
Search more.